BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35522916)

  • 21. Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer.
    Hughes RT; Gebeyehu RR; Kalada JM; Lycan TW; Frizzell BA; Kinney RD; D'Agostino RB; Bunch PM; Triozzi P; Zhang W; Furdui CM; Porosnicu M
    Future Oncol; 2023 Jul; 19(22):1523-1534. PubMed ID: 37199326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.
    Ngamphaiboon N; Chairoungdua A; Dajsakdipon T; Jiarpinitnun C
    Oral Oncol; 2023 Oct; 145():106520. PubMed ID: 37467684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combining radiotherapy and immunotherapy in definitive treatment of head and neck squamous cell carcinoma: review of current clinical trials.
    Plavc G; Strojan P
    Radiol Oncol; 2020 Oct; 54(4):377-393. PubMed ID: 33064670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
    Ferrarotto R; Amit M; Nagarajan P; Rubin ML; Yuan Y; Bell D; El-Naggar AK; Johnson JM; Morrison WH; Rosenthal DI; Glisson BS; Johnson FM; Lu C; Mott FE; Esmaeli B; Diaz EM; Gidley PW; Goepfert RP; Lewis CM; Weber RS; Wargo JA; Basu S; Duan F; Yadav SS; Sharma P; Allison JP; Myers JN; Gross ND
    Clin Cancer Res; 2021 Aug; 27(16):4557-4565. PubMed ID: 34187851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
    J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of radiation therapy-immunotherapy for head and neck cancers: Promises kept?
    Huguet F; Durand B; Atallah S; Prébet C; Richard S; Baujat B
    Cancer Radiother; 2021 Dec; 25(8):811-815. PubMed ID: 34711485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck - a case series and review of literature.
    Olmos M; Lutz R; Büntemeyer TO; Glajzer J; Nobis CP; Ries J; Möst T; Eckstein M; Hecht M; Gostian AO; Erdmann M; Foerster Y; Kesting M; Weber M
    Front Immunol; 2022; 13():970823. PubMed ID: 36389668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy for squamous cell carcinoma of the head and neck.
    Yokota T; Homma A; Kiyota N; Tahara M; Hanai N; Asakage T; Matsuura K; Ogawa T; Saito Y; Sano D; Kodaira T; Motegi A; Yasuda K; Takahashi S; Tanaka K; Onoe T; Okano S; Imamura Y; Ariizumi Y; Hayashi R;
    Jpn J Clin Oncol; 2020 Sep; 50(10):1089-1096. PubMed ID: 32776100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Systemic therapy strategies for head-neck carcinomas: current status].
    Hoffmann TK
    Laryngorhinootologie; 2012 Mar; 91 Suppl 1():S123-43. PubMed ID: 22456917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer (Review).
    Affolter A; Kern J; Bieback K; Scherl C; Rotter N; Lammert A
    Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35642667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus.
    Liu L; Xiang Z; Li Y; Guo W; Yang K; Wang J; Sun Z; Ren G; Zhang J; Sun M; Ran W; Huang G; Tang Z; Li L
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2022 Dec; 40(6):619-628. PubMed ID: 36416313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant immunotherapy in head and neck cancer: Rationale, current evidence and future perspective.
    Cabezas-Camarero S; Pérez-Segura P
    Crit Rev Oncol Hematol; 2022 Jan; 169():103569. PubMed ID: 34890800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemo- immunotherapy and radiation in locally advanced head and neck cancer: Where do we stand?
    Belgioia L; Becherini C; Bacigalupo A; Bonomo P
    Oral Oncol; 2022 Apr; 127():105773. PubMed ID: 35217401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrating Immunotherapy into Multimodal Treatment of Head and Neck Cancer.
    Rao YJ; Goodman JF; Haroun F; Bauman JE
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune checkpoint inhibitor use in head and neck squamous cell carcinoma: the current landscape and future perspectives.
    Gatfield ER; Tadross J; Ince W
    Future Oncol; 2024 Jun; ():1-17. PubMed ID: 38889284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy in HPV-Related Oropharyngeal Cancers.
    Roof L; Yilmaz E
    Curr Treat Options Oncol; 2023 Mar; 24(3):170-183. PubMed ID: 36719604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant chemotherapy or chemoradiotherapy in head and neck cancer.
    Jain P; Kumar P; Pai VR; Parikh PM
    Indian J Cancer; 2008; 45(3):83-9. PubMed ID: 19018109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
    Ferris RL; Spanos WC; Leidner R; Gonçalves A; Martens UM; Kyi C; Sharfman W; Chung CH; Devriese LA; Gauthier H; Chiosea SI; Vujanovic L; Taube JM; Stein JE; Li J; Li B; Chen T; Barrows A; Topalian SL
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy in head and neck squamous cell carcinoma: An updated review.
    Parmar K; Mohamed A; Vaish E; Thawani R; Cetnar J; Thein KZ
    Cancer Treat Res Commun; 2022; 33():100649. PubMed ID: 36279709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The research progress of PD-1/L1 inhibitors application in the treatment of head and neck squamous cell carcinoma].
    Song P; Yan X; Jiang Y; Ye Y; Wang J; Han P
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Apr; 36(4):315-320. PubMed ID: 35511629
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.